Literature DB >> 26902764

Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections.

Sylvain Goutelle1, Sandrine Roux2, Marie-Claude Gagnieu3, Florent Valour2, Sébastien Lustig4, Florence Ader5, Frédéric Laurent6, Christian Chidiac5, Tristan Ferry5.   

Abstract

The interindividual and intraindividual variabilities in daptomycin pharmacokinetics were investigated in 23 patients (69 pharmacokinetic profiles) who were treated for several months for bone and joint infections. Population daptomycin clearance was significantly influenced by renal function and was significantly higher in male than in female patients. We observed significant intraindividual changes in daptomycin clearance, which were uncorrelated with changes in renal function, suggesting that therapeutic drug monitoring is important in patients receiving prolonged daptomycin therapy.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26902764      PMCID： PMC4862545          DOI： 10.1128/AAC.02597-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Jane Marsh; Lesley A Stevens; John W Kusek; Frederick Van Lente
Journal:  Clin Chem       Date:  2007-03-01       Impact factor: 8.327

2.  Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.

Authors:  Antonello Di Paolo; Carlo Tascini; Marialuisa Polillo; Giulia Gemignani; Elisabet I Nielsen; Guido Bocci; Mats O Karlsson; Francesco Menichetti; Romano Danesi
Journal:  Int J Antimicrob Agents       Date:  2013-07-25       Impact factor: 5.283

3.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

4.  Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.

Authors:  Friederike Traunmüller; Michael V Schintler; Julia Metzler; Stephan Spendel; Oliver Mauric; Martin Popovic; Karl Heinz Konz; Erwin Scharnagl; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2010-04-07       Impact factor: 5.790

5.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

6.  Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.

Authors:  Jill M Butterfield; Bruce A Mueller; Nimish Patel; Katie E Cardone; Darren W Grabe; Noha N Salama; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

7.  Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment.

Authors:  Ricardo L Chaves; Abhijit Chakraborty; David Benziger; Stacey Tannenbaum
Journal:  J Antimicrob Chemother       Date:  2013-09-12       Impact factor: 5.790

8.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 9.  Fundamentals of population pharmacokinetic modelling: validation methods.

Authors:  Catherine M T Sherwin; Tony K L Kiang; Michael G Spigarelli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

10.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17
View more
  6 in total

1.  Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.

Authors:  Romain Garreau; Damien Montange; Antoine Grillon; François Jehl; Tristan Ferry; Laurent Bourguignon; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2022-08-16       Impact factor: 5.577

2.  Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients.

Authors:  Charalampos Antachopoulos; Stavroula Ilia; Paschalis Kadiltzoglou; Eirini Baira; Aristides Dokoumetzidis; Evangelos Gikas; Eleni Volakli; Maria Sdougka; George Briassoulis; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 3.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

Review 4.  Model-Informed Precision Dosing of Antibiotics in Osteoarticular Infections.

Authors:  Lingling Liu; Jin Wang; Huan Zhang; Mengli Chen; Yun Cai
Journal:  Infect Drug Resist       Date:  2022-01-11       Impact factor: 4.003

Review 5.  Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan.

Authors:  Fumiya Ebihara; Yukihiro Hamada; Hideo Kato; Takumi Maruyama; Toshimi Kimura
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

6.  Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.

Authors:  João Paulo Telles; Juliette Cieslinski; Felipe Francisco Tuon
Journal:  Braz J Infect Dis       Date:  2019-06-14       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.